PRENATAL EXPOSURE TO DIETHYLSTILBESTROL (DES) IN MALES AND GENDER-RELATED DISORDERS: RESULTS FROM A 5-YEAR STUDY
For many years, researchers and public health specialists have been assessing the human health impact of prenatal exposure to the estrogenic anti-miscarriage drug, diethylstilbestrol (commonly known as DES or “stilbestrol”). The scope of adverse effects in females exposed to DES (often called “DES daughters“) has been more substantially documented than the effects in males (“DES sons“). This paper contributes three areas of important research on DES exposure in males:
an overview of published literature discussing the confirmed and suspected adverse effects of prenatal exposure in DES sons;
preliminary results from a 5-year online study of DES sons involving 500 individuals with confirmed (60% of sample) and suspected prenatal DES exposure;
documentation of the presence of gender identity disorders and male-to-female transsexualism reported by more than 100 participants in the study.
Five shady ways Big Pharma may be influencing your doctor
” Until 2010, when the Physician Payments Sunshine Act passed, requiring doctors to disclose payments, the only thing better than working for Pharma was being a doctor wined and dined by Pharma…. … Trips to resorts and strip clubs will likely continue to diminish under the Physician Payments Sunshine Act, but there are many other ways, often sneaky, that Pharma can entice doctors to prescribe its expensive, patent drugs. ”
Hilda Bastian is cartoonist and writer at StatisticallyFunny blog
The “get in early!” assumption has an in-built tendency to lead us astray when it comes to detection of diseases and conditions. And even most physicians – just the people we often rely on to inform us – don’t understand enough about the pitfalls that lead us to jump to conclusions about early detection too, well…early.
Those who need it least get the most early detection
Over-diagnosis from detecting people who would never have become ill from the condition detected
The statistical effect that means survival rates “improve” even if no one’s life expectancy increases
Hilda Bastian is Editor etc at PubMed Health, blogger at Scientific American. Commenting on epidemiology with cartoons at Statistically funny.
A move by the Food and Drug Administration might make food nutrition labels easier for you to read and understand. A Professor of Health at the University of South Florida has a wish list on what she wants changed and shares how this will affect us all.
Tous les deux ans, Prescrire propose deux jours de rencontres pluri-professionnelles. Des moments forts, d’échanges, de débats et d’ateliers auxquels participent professionnels et usagers. Pour l’édition 2014, prévue les 23 et 24 mai à Paris, l’équipe Prescrire vous propose un thème ambitieux:
Préparer l’avenir pour mieux soigner
Quel avenir ? Celui d’une organisation des soins au service des patients ; d’une recherche en soins primaires active ; et aussi de la formation professionnelle ; des pratiques pluriprofessionnelles ; du parcours de soins ; du rôle des usagers du système de soins ; etc. l’avenir des soins, à l’échelle des professionnels de santé et des usagers.
Creuset d’échanges et de partages, les Rencontres Prescrire 2014 sont conçues sur le modèle des éditions précédentes :
une exposition de posters, présentant les travaux de participants, en rapport avec le thème
un programme d’échanges en groupes constitué de réunions plénières et d’ateliers
Are feds flubbing a program to take endocrine disruptors seriously?
Endocrine disruptors are chemicals or man-made toxins which, when absorbed, have been shown to mimic the action of hormones. They can turn on, turn off, or change normal signals. They can alter normal hormone levels, trigger excessive action, or completely block a natural response. Any other bodily function controlled by hormones can also be affected.
Lord Saatchi’s Medical Innovation Bill “the SaatchiBill” would help doctors innovate new treatments and cures for cancer and other diseases
” Lord Saatchi’s Medical Innovation Bill “the Saatchi Bill” will help doctors innovate new treatments and cures for cancer and other diseases.
The Medical Innovation Bill will save lives by supporting doctors who want to innovate and find new ways of treating disease.
Doctors, patients and judges will have much greater clarity as to what is negligent and dangerous practice by clinicians and what is careful and sensible innovation.
It will free your doctor to consider new treatments and ideas. But, and more importantly, it will allow the patient to demand innovative treatment.
One of the most famous examples of innovation is when Geoffrey Keynes, a doctor at Barts, refused to do what surgeons across the UK and US were doing with breast cancer – the Halsted method – whereby women with breast cancer faced a double mastectomy, and the removal of all tissue from the shoulder, to the chest wall, to ribs – anything and everything that could be removed without killing the women.
Keynes, alone, removed only the tumour and undertook radiotherapy, in combination. He was ridiculed and humiliated on a world stage. Halsted followers called it a ‘lumpectomy’ as a term of derision. Of course, today, the lumpectomy is standard procedure.
That was innovation.
Once passed, a patient, armed with the legislation, will be able to say to his or her doctor: ‘Are you trying everything? Can you do anything differently?’ The doctor will no longer need to say he or she cannot risk trying anything new. ”
L’APESAC – Association d’Aide aux Parents d’Enfants souffrant du Syndrome de l’Anti-Convulsivant – a conçu une plaquette d’information double face recto et verso sur l’embryofoetopathie au Valproate
Le syndrome de l’anti-convulsivant est encore très largement méconnu. Les témoignages qui nous arrivent font état de médecins, neurologues, obstétriciens qui encore aujourd’hui ne parlent pas aux femmes des risques liés à la prise de valproate de sodium pendant la grossesse.
Synthetic estrogens adverse effects can be passed on to subsequent generations
The synthetic estrogen diethylstilbestrol (DES) is well documented to be a perinatal carcinogen in both humans and experimental animals. Exposure to DES during critical periods of differentiation permanently alters the programming of estrogen target tissues resulting in benign and malignant abnormalities in the reproductive tract later in life. Using the perinatal DES-exposed rodent model, cellular and molecular mechanisms have been identified that play a role in these carcinogenic effects. Although DES is a potent estrogenic chemical, effects of low doses of the compound are being used to predict health risks of weaker environmental estrogens. Therefore, it is of particular interest that developmental exposure to very low doses of DES has been found to adversely affect fertility and to increase tumor incidence in murine reproductive tract tissues. These adverse effects are seen at environmentally relevant estrogen dose levels. New studies from our lab verify that DES effects are not unique; when numerous environmental chemicals with weak estrogenic activity are tested in the experimental neonatal mouse model, developmental exposure results in an increased incidence of benign and malignant tumors including uterine leiomyomas and adenocarcinomas that are similar to those shown following DES exposure. Finally, growing evidence in experimental animals suggests that some adverse effects can be passed on to subsequent generations, although the mechanisms involved in these trans-generational events remain unknown. Although the complete spectrum of risks to DES-exposed humans are uncertain at this time, the scientific community continues to learn more about cellular and molecular mechanisms by which perinatal carcinogenesis occurs. These advances in knowledge of both genetic and epigenetic mechanisms will be significant in ultimately predicting risks to other environmental estrogens and understanding more about the role of estrogens in normal and abnormal development.